China Sky One Medical increases full year revenue, net income guidance
China Sky One Medical (Nasdaq: CSKI), a pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC") announced ‘record financial results’ for the first quarter of 2010.
Total revenues in the 3 month period ended March 31, 2010 rose
16.4% to $28.9 million year over year, with gross profits climbing 15%
to $21.6 million and operating income climbing 11.8% to just over $10
million. The strong headline numbers were largely thanks to strong
sales from the company's ‘ointment and other’ product categories, which
represented around 56% of total group revenues. Sales of ointments grew
strongly, up 53.6% to $7.8 million – one product, Compound Camphor
Cream, represented 10.5% of total revenues in the first quarter. Sales
of ‘Other Products’ grew 82% in the current year quarter to $8.4 million
– lead by solid demand for Naphazoline Hydrochloride eye drops, Napadil
tablet and Tinea liniment.
The robust growth in ointments and other products was partially
softened by a 9.9% decline in patch products to $8.2 million, which was
blamed on tighter regulations related to promoting weight loss products
on TV.
GAAP net income increased 73.8% to $12.6 million, or 74 cents
per diluted share – though the figure was massaged by a non-cash gain in
the fair value of a derivative warrant liability. Excluding the
non-cash gain, net income climbed 5.8% to $7.7 million, or 45 cents per
share.
"Our first quarter double-digit revenue growth was partly driven
by strength in the sales of our ointment products, including Compound
Camphor Cream, which grew nearly 54% year-over-year and has become our
best selling product," said Mr. Yan-Qing Liu, Chairman and CEO of China
Sky One Medical, Inc. "While Slim Patch sales were adversely affected by
new government restrictions limiting the promotion of weight loss
products on TV and sales of our diagnostic kits were lower due to
limited internal promotional support in the first quarter, we remain
confident in our outlook to accelerate revenue growth in the coming
quarters, driven by increased sales, marketing and distribution of our
rich portfolio of over 90 products and new product launches."
Operating expenses increased 18% year-over-year to $11.5 million
in the first quarter of 2010, mainly due to a $1.4 million increase in
R&D expenses.
As of March 31, 2010, China Sky One had $65.4 million in cash and
equivalents.
Looking ahead, the Nasdaq listed group said it was now revising
revenue guidance for the full year to $160-$164 million and net income
guidance to $40-$41 million.
“The first quarter is typically the slowest period, partly due to
a temporary slowdown in customer orders during the Chinese New Year
holiday. China Sky One's management expects revenue growth to accelerate
in future quarters, driven by further optimization of the Company's
distribution channels and enhancement of product promotional efforts,
and is confident in achieving the 2010 financial guidance,” the company
added.
Related news
- Regency Mines shares up on more positive Mambare results
- Escher Group wins largest contract to date; shares surge
- Chariot Oil & Gas completes 3D seismic survey in Namibia
- Peninsula Energy chairman talks to Proactive Investors in Stocktube Video
- Empire Energy Group hits oil production milestone in Appalachia
- Aminex and Solo Oil to carry out further analysis on Ntorya-1 well
- Angel Biotechnology shares surge as it reveals new contracts worth total of £4.5mln
